GlaxoSmithKline PLC GSK StarRatingValueLabel_3

Last Price
1,676.00
Day Change
-10.00|-0.59%

As of 18/06/2013
17:08:09 BST | GBX  Minimum 15 Minutes Delay.

Bid/OfferDay RangeVolume90d Ave VolMkt Cap
1,650.00 - 1,682.501,670.00 - 1,690.505,656,285- 82,446.429
Last Close52 Week RangeP/EYield %ISIN
1,686.001,314.00 - 1,816.0018.414.30GB0009252882

GlaxoSmithKline Share Price

Morningstar's Take GSK

As one of the world's largest pharmaceutical companies, GlaxoSmithKline has used its vast resources to create the next generation of medicines. The company's innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat, in our opinion.

Fair Value Estimate

1,777.00 GBX

Uncertainity

Average

Economic Moat

Wide

Financial Health

Financial Health

Total Returns

 Chg (%)  
3yr, 5yr & 10yr performance data is annualised.
GlaxoSmithKline PLC-2.13 
FTSE 100 TR GBP-4.79
 
Financials
Annual
201020112012
more...
Income Statement
Turnover28,392.0027,387.0026,431.00
Operating Profit3,783.007,807.007,392.00
Net Profit1,853.005,458.004,744.00
Reported EPS31.90103.2091.50
Balance Sheet
Current Assets16,020.0015,502.0013,628.00
Non Current Assets26,194.0024,913.0027,783.00
Total Assets42,230.0041,080.0041,475.00
Current Liabilities12,794.0015,010.0013,815.00
Total Liabilities32,485.0032,253.0034,728.00
Total Equity9,745.008,827.006,747.00
Cash Flow
Cash From Operations8,631.007,713.006,048.00
Change in Net Cash-642.00-94.00-1,607.00
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
more...
'Broker Forecasts' provides consensus figures based on several brokers' views
20136928.30115.2826.6514.540.5577.304.61
20147800.12127.2810.4113.171.2782.004.89

Regulatory News

Director Dealings
TradedActionNotifierPriceAmountValue
more...
11/06/2013PurchaseSir Andrew Witty1658.927116.00
11/06/2013Transfer inSir Andrew Witty0.0070.00
11/06/2013PurchaseSimon Dingemans1658.927116.00
11/06/2013Transfer inSimon Dingemans0.0070.00

Company Profile

GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Sector

Healthcare

Industry

Drug Manufacturers - Major

Stock Style

Large-Value

Fiscal Year Ends

December

Employees

98681

Outlook

(24/04/2013) "In 2013, GSK expects core EPS growth of 3.00-4.00% CER with turnover growth of around 1.00% CER"

Next Event 08/05/2013

Ex Dividend
Ratios
 CompSecMkt
PER (E)13.8712.9813.21
Div Yld (E)4.744.963.98
PEG (E)0.76-0.500.02
ROCE43.4851.1514.54
Op Mrgn25.1218.817.77
EPS Grwth18.2212.9115.85
Dividends
PreviousLatest
more...
Declared Date16/11/1222/02/13
Ex-Div14/11/1220/02/13
Paid03/01/1311/04/13
Amnt p18.0022.00

Broker Forecasts

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
more...
Directors
more...
ChairmanSir Christopher Gent
Chief Executive OfficerSir Andrew Witty
Chief Financial OfficerSimon Dingemans
HelpGlossaryLicensing OpportunitiesData OpportunitiesCareersContact MorningstarAdvertiseSite Map
   
Make this site my homepage
© Copyright 2012 Morningstar. All rights reserved. Terms of Use | Privacy Policy | Cookies